文献速递胸部肿瘤泌尿男性生殖肿瘤骨软组织肉瘤与黑色素瘤

进展性疾病模式剖析用于免疫治疗改良分类

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.
PubMed 文献 · JAMA Oncol · 2025-01-01

该研究基于5项3期试验中1377例接受阿替利珠单抗治疗的实体瘤患者,根据靶病灶和非靶病灶增大或新病灶的组合识别出7种进展模式,并开发出将进展分为低、中、高危三级的改良分类,该分类与进展后生存相关并在多瘤种中得到验证。

要点

  • 在肾细胞癌中,7种进展模式显著影响预后,6个月进展后生存概率从26%到90%不等。
  • 改良分类将进展分为低危(仅现有病灶进展)、中危(新病灶无现有病灶进展)、高危(现有病灶进展加新病灶)。
  • 与高危进展相比,低危进展的风险比为0.23(95%CI 0.13-0.41;P<.001),中危进展的风险比为0.39(95%CI 0.23-0.66;P<.001)。

核心结论

  • 基于进展模式开发的生存评分所定义的风险分类与接受免疫治疗的多种实体瘤患者的进展后生存相关,可能有助于改善预后判断和临床决策。

研究设计与样本

  • 该研究为对5项3期试验(IMmotion151、IMvigor211、OAK、IMpower133和IMspire150)的事后分析,共纳入1377例接受阿替利珠单抗治疗的肾细胞癌、尿路上皮癌、小细胞肺癌、非小细胞肺癌和黑色素瘤患者,分析于2024年3月至9月进行。

主要发现

  • 在肾细胞癌中,7种进展模式显著影响预后,6个月进展后生存概率从靶病灶和非靶病灶进展加新病灶的26%到仅靶病灶或非靶病灶进展的90%不等。
  • 与高危进展相比,低危进展的风险比为0.23(95%CI 0.13-0.41;P<.001),中危进展的风险比为0.39(95%CI 0.23-0.66;P<.001)。
  • 在其他试验中的验证证实该评分适用于多种肿瘤。

关键数值与推荐

  • 改良进展分类将进展分为3个风险等级:低危(现有病灶进展)、中危(新病灶无现有病灶进展)、高危(现有病灶进展加新病灶)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Progressive disease (PD) in patients treated with immune checkpoint inhibitors (ICIs) varies widely in outcomes according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Efforts to modify RECIST for ICI treatment have not resolved the heterogeneity in PD patterns, posing a clinical challenge. OBJECTIVE: To develop and validate a modified PD classification based on PD patterns and evaluate its association with postprogression survival (PPOS) in patients treated with the programmed cell death protein ligand 1 antibody atezolizumab across various solid tumors. DESIGN, SETTING, AND PARTICIPANTS: This study analyzed data from 5 phase 3 trials (IMmotion151, IMvigor211, OAK, Impower133, and IMspire150) involving patients treated with atezolizumab for renal cell carcinoma (RCC), urothelial carcinoma, small cell lung cancer, non-small cell lung cancer, and melanoma. This post hoc analysis was conducted from March to September 2024. EXPOSURE: Treatment with atezolizumab. MAIN OUTCOMES AND MEASURES: The primary outcome was the association of PD patterns with PPOS. Seven PD patterns were identified based on the enlargement of target and nontarget lesions or new lesions and their combinations. RESULTS: A total of 1377 patients were analyzed across the 5 trials. In RCC, 7 PD patterns significantly affected prognosis. The 6-month PPOS probability ranged from 26% for progression in target and nontarget lesions plus new lesions to 90% for progression in either target or nontarget lesions alone. A modified PD classification was developed that categorized PD into 3 risk levels: low risk (progression of existing lesions), intermediate risk (new lesions without progression of existing lesions), and high risk (progression of existing lesions plus new lesions). This score was associated with PPOS in ICI-treated RCC, with hazard ratios of 0.23 (95% CI, 0.13-0.41; P < .001) and 0.39 (95% CI, 0.23-0.66; P < .001) for low-risk and intermediate-risk PD compared with high-risk PD, respectively. Validation in additional trials confirmed the score's applicability across various tumors. CONCLUSIONS AND RELEVANCE: In this study, a survival score was developed based on PD patterns. The risk classification was associated with PPOS across various solid tumors treated with immunotherapy and may therefore enhance prognostication and clinical decision-making, potentially providing a valuable tool for treating patients with PD who are receiving immunotherapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Saal J, Eckstein M, Ritter M, et al. Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy. JAMA Oncol. 2025. PMID: 39724246. doi:10.1001/jamaoncol.2024.5672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。